BRPI0513317A - ciclosporinas para tratar doença de alzheimer - Google Patents

ciclosporinas para tratar doença de alzheimer

Info

Publication number
BRPI0513317A
BRPI0513317A BRPI0513317-3A BRPI0513317A BRPI0513317A BR PI0513317 A BRPI0513317 A BR PI0513317A BR PI0513317 A BRPI0513317 A BR PI0513317A BR PI0513317 A BRPI0513317 A BR PI0513317A
Authority
BR
Brazil
Prior art keywords
cyclosporins
disease
treat alzheimer
alzheimer
treat
Prior art date
Application number
BRPI0513317-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Dalia Cohen
Larry Alexander Gaither
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0513317A publication Critical patent/BRPI0513317A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0513317-3A 2004-07-13 2005-07-12 ciclosporinas para tratar doença de alzheimer BRPI0513317A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58777004P 2004-07-13 2004-07-13
PCT/EP2005/007556 WO2006005580A1 (en) 2004-07-13 2005-07-12 Cyclosporins to treat alzheimer’s disease

Publications (1)

Publication Number Publication Date
BRPI0513317A true BRPI0513317A (pt) 2008-05-06

Family

ID=35276396

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513317-3A BRPI0513317A (pt) 2004-07-13 2005-07-12 ciclosporinas para tratar doença de alzheimer

Country Status (10)

Country Link
EP (1) EP1893226A1 (es)
JP (1) JP2008512351A (es)
KR (1) KR20070036127A (es)
CN (1) CN1984670A (es)
AU (2) AU2005261838A1 (es)
BR (1) BRPI0513317A (es)
CA (1) CA2573400A1 (es)
MX (1) MX2007000502A (es)
RU (1) RU2007105141A (es)
WO (1) WO2006005580A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5322647B2 (ja) 2005-09-30 2013-10-23 スシネキス インク ウイルス感染の治療及び予防のためのシクロスポリンａのアリールアルキル及びヘテロアリールアルキル誘導体
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
ATE502633T1 (de) 2006-05-19 2011-04-15 Scynexis Inc Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
US20100291074A1 (en) * 2007-07-27 2010-11-18 Columbia University In The City Of New York Cyclophilin d-amyloid beta interaction potentiates mitochondrial dysfunction in a transgenic mouse model of alzheimer's disease
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
WO2010002428A2 (en) * 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
AU2009334790B2 (en) 2008-12-31 2016-09-08 Scynexis, Inc. Derivatives of cyclosporin A
EP2509615A1 (en) * 2009-12-09 2012-10-17 Scynexis, Inc. Novel cyclic peptides
KR20120035622A (ko) * 2010-10-06 2012-04-16 서울대학교산학협력단 Ｖｄａｃ1 단백질 조절을 통한 파킨슨씨병 치료방법
CN102586121B (zh) * 2012-02-21 2013-07-10 淮海工学院 一种产乙酰胆碱酯酶抑制剂的真菌及其用途
EP2900684A2 (en) 2012-09-29 2015-08-05 Novartis AG Cyclic peptides and use as medicines
EP2908841A4 (en) * 2012-10-19 2016-05-25 Scynexis Inc NEW ANTIVIRAL MACROCYCLES
CN106620648A (zh) * 2016-12-30 2017-05-10 山东景源生物科技有限公司 一种阻断帕金森患者淋巴细胞周期的药物及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0484281B2 (en) * 1990-11-02 2000-11-22 Novartis AG Cyclosporins
JP3089350B2 (ja) * 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド シクロフィリンロタマーゼ活性の阻害剤
US20030103959A1 (en) * 2001-06-22 2003-06-05 Hughes Paul E. Methods of providing neuroprotection and/or neurorestoration via the neural activin type IIB receptor

Also Published As

Publication number Publication date
CA2573400A1 (en) 2006-01-19
RU2007105141A (ru) 2008-08-20
WO2006005580A1 (en) 2006-01-19
AU2009210375A1 (en) 2009-09-10
AU2005261838A1 (en) 2006-01-19
EP1893226A1 (en) 2008-03-05
KR20070036127A (ko) 2007-04-02
CN1984670A (zh) 2007-06-20
JP2008512351A (ja) 2008-04-24
MX2007000502A (es) 2007-03-08

Similar Documents

Publication Publication Date Title
BRPI0513317A (pt) ciclosporinas para tratar doença de alzheimer
MY162640A (en) Thioninium compounds and their use
BRPI0414062B8 (pt) uso de ciclosporinas modificadas para o tratamento de distúrbios por hcv
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
BR0211905A (pt) Dialdeìdos de rapamicina
GB0421639D0 (en) Methods and compositions relating to alzheimer's disease
MX2008009947A (es) Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos.
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
DOP2009000269A (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
MY147247A (en) Organic compounds and their uses
EA200801481A1 (ru) 5-(арилсульфонил)пиразолопиперидины
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
UA94580C2 (ru) Аналог 39-дезметоксирапамицина, способный преодолевать гематоэнцефалический барьер, для лечения патологического состояния, вызванного нейрогенным повреждением или заболеванием
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
BRPI0911482A2 (pt) Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer
PL1910338T3 (pl) Związki heterotetracykliczne jako mimetyki TPO
TNSN07240A1 (en) Compounds for flaviviridae treatment
MX2008002166A (es) Compuestos y composiciones como mimeticos de trombopoietina (tpo).
TWI372620B (en) Treatment of autoimmune diseases
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
GT201100336A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
BRPI0509477A (pt) compostos de sulfonamida para o tratamento de distúrbios neurodegenerativos

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 6A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS ANUIDADES EM DEBITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2330 DE 01-09-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.